NL-OMON44463CompletedNot Applicable
istening effort in the European population: A new innovative program of research and training - LISTE
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 171
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 12 to 99 (—)
Inclusion Criteria
- •Age between 18 and 80 years, native Dutch speaker, normal or corrected to normal eyesight, for normally hearing listeners: age -normal hearing according to ISO 7029, 2000, for listeners with hearing loss: pure tone hearing thresholds (average across 1, 2, 4 kHz) of at least 25 dB HL in at least one ear. ;For experiment 4C: Aged 12 years up to and including 16 years, native speakers of Dutch, normal or corrected-to-normal eyesight. Listeners with hearing loss should use at least one hearing aid in daily-life. Furthermore the hearing-impaired children should have a moderately to severe binaural sensorineural hearing loss (* 35 dB HL and * 70 dB HL for both ears), and be experienced hearing aid users. Children with normal hearing should have air-conduction pure-tone thresholds of max. 20 dB HL at the octave frequencies between 500 and 4000 Hz.
Exclusion Criteria
- •dyslexia or other reading problems, history of neurological or psychiatric diseases, eye diseases such as caused by diabetes mellitus and cataract.;Supplementary for experiment 4C: General exclusion criteria: not being able to attend regular education schools. For the hearing impaired children unilateral and conductive hearing losses are excluded.
Investigators
Similar Trials
Completed
Phase 2
A Prospective, Multicenter, European Registry Investigating the Lutonix Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis within Bare-Metal Stentsrestenotic lesions - stenosis10011082NL-OMON33458utonix20
Active, not recruiting
Not Applicable
Evaluation of the effectiveness and transferability of the digital health platform (ProACT) to support home-based multimorbidity self-management in EuropeMultimorbidity consisting of two or more of any of the following:1. Diabetes2. Chronic Respiratory Disease (i.e., COPD, Chronic Bronchitis, Emphysema, and Chronic Asthma)3. Chronic Heart Disease, Coronary Artery Disease, and Cardiovascular Disease (i.e., Hypertension, Atherosclerosis, Angina, and Arrhythmia)4. Chronic Heart FailureISRCTN34134007Trinity College Dublin2,220
Completed
Not Applicable
eurofeedback a possible effective intervention for youth with AD(H)D and comorbid severe behavioral problems.Attention Deficit Hyperactivity DisorderNL-OMON31819GGZ Eindhoven (Eindhoven)28
Completed
Not Applicable
*REGISTRY - an observational study of the European Huntington's Disease Network (EHDN)*Huntington's disease10028037NL-OMON38177eids Universitair Medisch Centrum800
Active, not recruiting
Not Applicable
Full title: A European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with dyslipidemia with or without other comorbiditiesShort title: European Trial about Effect of RimoNabant on Abdominal obese patients with dysLipidemia (ETERNAL) - ETERNAabdominally obese patients with dyslipidemia with or without other comorbiditiesMedDRA version: 8.1Level: LLTClassification code 10059179Term: Abdominal obesityEUCTR2006-001715-30-SIsanofi aventis Groupe1,440